SPHS - Sophiris Bio, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3550
+0.0050 (+1.43%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.3500
Open0.3600
Bid0.0000 x 38800
Ask0.0000 x 800
Day's Range0.3520 - 0.3880
52 Week Range0.3400 - 2.1900
Volume141,514
Avg. Volume201,689
Market Cap12M
Beta (3Y Monthly)1.20
PE Ratio (TTM)355.00
EPS (TTM)0.0010
Earnings DateNov 9, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.25
  • Zacks Small Cap Research

    SPHS: Single Phase 3 Clinical Trial Planned for Topsalysin in Localized Prostate Cancer…

    By David Bautz, PhD NASDAQ:SPHS READ THE FULL SPHS RESEARCH REPORT Business Update Sophiris Bio Inc. (NASDAQ:SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic

  • GlobeNewswire

    Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 -- Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class,.

  • Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design
    PR Newswire

    Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

    The Phase 3 study design agreed upon with the FDA is consistent with the design previously agreed upon with the European Medicines Agency, as reported in June of this year. The study will enroll approximately 700 patients with a confirmed diagnosis of localized intermediate risk disease, to be equally randomized to receive a single administration of either topsalysin or placebo.

  • Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering
    PR Newswire

    Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced the completion of its previously announced registered direct offering of 5,333,334 common shares (or pre-funded warrants to purchase common shares) for an effective price of $0.75 per share with a single healthcare-focused institutional investor. In addition to the common shares (or pre-funded warrants to purchase common shares), in a concurrent private placement, Sophiris issued the investor warrants to purchase up to 5,333,334 common shares (the "purchase warrants"), which represent 100% of the number of common shares (or pre-funded warrants to purchase common shares) issued in the registered direct offering, with an exercise price of $0.95 per share and a five-year exercise period commencing six (6) months following the issuance date of such purchase warrants.

  • Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
    PR Newswire

    Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 3:00 p.m. EDT in New York, NY. Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases.

  • Zacks Small Cap Research

    SPHS: Awaiting Feedback from FDA on Phase 3 Plan for Topsalysin in Prostate Cancer…

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.

  • Sophiris Bio Announces $4.0 Million Registered Direct Offering
    PR Newswire

    Sophiris Bio Announces $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 27, 2019 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 5,333,334 of its common shares (or pre-funded warrants to purchase common shares) for an effective price of $0.75 per share, for gross proceeds of approximately $4.0 million, in a registered direct offering. The offering is expected to close on or about August 29, 2019, subject to the satisfaction of customary closing conditions. In addition to the securities described above, in a concurrent private placement, Sophiris will issue to the investor warrants to purchase up to 5,333,334 common shares, which represent 100% of the number of common shares issued in the registered direct offering, with an exercise price $0.95 per share and a five-year exercise period commencing six (6) months of the issuance date.

  • Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
    PR Newswire

    Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia , Aug. 9, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Zacks Small Cap Research

    SPHS: Details of Phase 3 Prostate Cancer Trial Based on Positive EMA Feedback…

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.

  • Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design
    PR Newswire

    Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

    SAN DIEGO and VANCOUVER, British Columbia, June 19, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that it has received formal scientific advice from the European Medicines Agency (EMA) regarding a proposed design of a Phase 3 clinical trial to evaluate the potential of topsalysin as a targeted focal therapy to treat patients with intermediate risk localized prostate cancer. "Based on the safety profile of topsalysin in 451 patients in our clinical development program along with the efficacy seen in our Phase 2 studies in localized prostate cancer, we approached the EMA with our proposed study design for a single Phase 3 trial to support registration in Europe, and we are pleased to have now obtained formal feedback from the Agency," said Randall Woods, president and CEO of Sophiris.

  • Some Sophiris Bio (FRA:BFF1) Shareholders Have Taken A Painful 79% Share Price Drop
    Simply Wall St.

    Some Sophiris Bio (FRA:BFF1) Shareholders Have Taken A Painful 79% Share Price Drop

    Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...

  • Zacks Small Cap Research

    SPHS: EMA Guidance on Phase 3 Clinical Trial for Topsalysin Expected in 2Q19…

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.

  • Sophiris Bio Reports First Quarter 2019 Financial Results
    PR Newswire

    Sophiris Bio Reports First Quarter 2019 Financial Results

    SAN DIEGO and VANCOUVER, British Columbia , May 9, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing ...

  • Sophiris Bio to Present at Two Upcoming Investor Conferences
    PR Newswire

    Sophiris Bio to Present at Two Upcoming Investor Conferences

    SAN DIEGO and VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present at two upcoming healthcare-focused investor conferences. On Monday, April 8, 2019, Mr. Woods will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference at 12:10 pm BST in London, England.  On Wednesday, April 10, 2019, Mr. Woods will present a corporate overview at the 18th Annual Needham Healthcare Conference at 2:50 pm EDT in New York, NY.

  • Zacks Small Cap Research

    SPHS: Awaiting Regulatory Guidance for Topsalysin Phase 3 Study…

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.

  • Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
    PR Newswire

    Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the fourth quarter and full year 2018 and recent corporate highlights. "During the past year, Sophiris has made important progress in determining the ideal method for topsalysin administration as a focal treatment for localized prostate cancer," said Randall E. Woods, president and CEO of Sophiris. "The Phase 2b study provided a compelling look at this potential, showing that a single administration of topsalysin led to a clinical response in 27% of patients, including a complete ablation of tumor in 16% of patients.

  • Zacks Small Cap Research

    SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…

    A total of 38 patients received a single administration of topsalysin to treat a clinically significant tumor, which was defined for this study as either a Gleason score of 6 (pattern 3 + 3) and greater than or equal to 6 mm maximum cancer core length (MMCL), or a Gleason score of 7 (pattern 3 + 4) and less than or equal to 10 mm MCCL. Ten patients received a second administration of topsalysin due to having a partial response to the first treatment, however their lesions were still clinically significant.

  • Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
    PR Newswire

    Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial

    SAN DIEGO and VANCOUVER, British Columbia, Dec. 17, 2018 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today provides an update from its Phase 2b study of topsalysin for localized prostate cancer, including top-line safety and biopsy results from the patients who received a second administration of study drug, which appeared to be safe and generally well-tolerated. Additional benefit was not observed on targeted biopsy six months after re-treatment with a second administration of topsalysin. As previously stated, a total of 27% of patients (10/37) demonstrated a clinical response six months following a single administration of topsalysin.